Full video transcriptClick to expand
Auto-generated transcript of @anniemd007's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00You know you've been on a GOP one for three years when.
- 0:05Now I'm going to try and see if I can take this.
- 0:07This was a cheese ball container from Walmart.
- 0:11And I'm going to see if CBS will take them for me.
- 0:14Will they give you, is it like recycling? Will they give you money for each one?
- 0:17I wish.
- 0:18Well you should give me $550 for each one.
- 0:21This is how much you, that's what we should do is guess how much.
- 0:25What's the price?
- 0:27Guess how much if each one of these costs $550 fucking dollars?
- 0:32For knowledge one.
- 0:33Yes, oh no, oh yeah. Every four.
- 0:36If four of these is $550, how much do you think this is worth?
- 0:41But you don't, you haven't counted them so you can't tell people if they're right or wrong.
- 0:47We could guess.
- 0:49Okay.
- 0:52So guess how much is in here.
- 0:54If four of these is $550, can you guess how much?
- 0:58This is a cheese ball container from Walmart.
- 1:00Just FYI, that's my sharps container.
- 1:02I'm here at CBS gonna see if they will take the sharps here.
- 1:05Cause otherwise I don't know what to do with them.
- 1:09Apparently CBS does not take sharps.
- 1:11So they gave me information.
- 1:13I will try and link the QR code here where you can dispose of your sharps.
- 1:17Cause I got three years of stuff.
- 1:22The first person to comment the exact number of pens in the container
- 1:27is going to get a wellness care package from me.
- 1:30So like, follow, share, do all the things.
GLP-1 pen giveaways on TikTok: fun trend or regulatory minefield?
Quick answer
GLP-1 receptor agonist use has expanded rapidly since 2021, with millions of patients now self-administering weekly subcutaneous injections at home, creating a significant and underregulated household sharps disposal burden. The creator's three-year duration of use is consistent with long-term weight management protocols now supported by the SELECT trial (Lincoff et al., 2023, NEJM), which demonstrated cardiovascular benefit with sustained semaglutide use. Proper sharps disposal is not just a regulatory formality: needlestick injuries from improperly discarded sharps cause an estimated 600,000 to one million injuries annually in the U.S., many outside clinical settings (EPINet, 2020).
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 pen giveaways on TikTok: fun trend or regulatory minefield?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
GLP-1 pen giveaways on TikTok: fun trend or regulatory minefield? is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "GLP-1 pen giveaways on TikTok: fun trend or regulatory minefield?" from Annie DeGracia Anderson. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonist use has expanded rapidly since 2021, with millions of patients now self-administering weekly subcutaneous injections at home, creating a significant and underregulated household sharps disposal burden.
The reason this review is not generic is the source wording and the canonical claim label "glp1 shall we play a game the first person to comment and guess t." In this clip, the useful excerpt is: "You know you've been on a GOP one for three years when." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
GLP-1 receptor agonist use has expanded rapidly since 2021, with millions of patients now self-administering weekly subcutaneous injections at home, creating a significant and underregulated household sharps disposal burden.
FormBlends verdict
GLP-1 social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- GLP-1 receptor agonist use has expanded rapidly since 2021, with millions of patients now self-administering weekly subcutaneous injections at home, creating a significant and underregulated household sharps disposal burden. The creator's three-year duration of use is consistent with long-term weight management protocols now supported by the SELECT trial (Lincoff et al., 2023, NEJM), which demonstrated cardiovascular benefit with sustained semaglutide use. Proper sharps disposal is not just a regulatory formality: needlestick injuries from improperly discarded sharps cause an estimated 600,000 to one million injuries annually in the U.S., many outside clinical settings (EPINet, 2020).
- FDA-cleared sharps containers cost $5 to $15 and meet puncture-resistance standards that repurposed food containers do not. Use one.
- Fewer than 40% of U.S. counties have a publicly accessible sharps drop-off site within 10 miles of residential areas (Yanklowitz et al., 2021, Waste Management), making this a real infrastructure gap.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- FDA-cleared sharps containers cost $5 to $15 and meet puncture-resistance standards that repurposed food containers do not. Use one.
- Fewer than 40% of U.S. counties have a publicly accessible sharps drop-off site within 10 miles of residential areas (Yanklowitz et al., 2021, Waste Management), making this a real infrastructure gap.
- CVS and other retail pharmacies do not uniformly accept used sharps. Check SafeNeedleDisposal.org for authorized sites in your zip code before making the trip.
- Brand-name GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound) carry list prices of roughly $900 to $1,350 per month as of 2024. Out-of-pocket costs vary significantly with insurance and manufacturer savings programs.
- Weekly GLP-1 injections over 3 years produce approximately 156 used devices. The sharps disposal burden from GLP-1 adoption is a population-level waste management issue that pharmacy systems have not caught up with.
- Needlestick injuries from improperly discarded sharps cause an estimated 600,000 to 1 million injuries annually in the U.S. outside clinical settings (EPINet, 2020). This is not a theoretical risk.
- Do not flush GLP-1 injection pens. FDA flush guidance covers only specific listed opioids and does not include injectable diabetes or weight-loss medications.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @anniemd007 actually say?
The creator filmed herself driving to CVS with a repurposed Walmart cheese ball container full of used GLP-1 injection pens, hoping the pharmacy would take them as a sharps disposal. She also set up a giveaway: guess the exact number of pens and the total dollar amount spent, win a wellness care package. Her cost reference point was "$550" per four pens, which she used as the math basis for the guessing game.
To be clear, she was not making clinical claims. This video is about sharps disposal logistics and cost transparency, not medical advice. That actually makes it easier to fact-check, because the claims are concrete and verifiable.
Does the science back this up?
On the disposal question, she is essentially correct that most retail pharmacies do not operate take-back programs for used sharps, and that is a real, documented public health gap. The FDA and EPA have both flagged household sharps disposal as a persistent problem, particularly as GLP-1 prescriptions have surged.
The FDA's sharps disposal guidance (updated 2022) explicitly states that mail-back programs, community collection sites, and authorized collectors are the preferred options for patients. Drop boxes at pharmacies exist in some states but are far from universal. A 2021 study by Yanklowitz et al. in Waste Management found that fewer than 40% of U.S. counties have a publicly accessible sharps drop-off site within 10 miles of residential areas. CVS does participate in some drug take-back programs nationally, but used injection devices are handled inconsistently by location and state regulation. So her CVS trip coming up empty is not surprising, and frankly expected in most markets.
What did they get wrong (or right)?
She got the core disposal advice right: do not trash loose sharps, find an authorized collection point. Credit where it is due. But there are a few issues worth flagging.
First, the cheese ball container. It looks sturdy and has a lid, but it is not an FDA-cleared sharps container. The FDA requires sharps containers to be puncture-resistant, leak-proof on sides and bottom, and have a tight-fitting lid. A plastic cheese ball jar from Walmart has not been tested to those standards. For storage at home over three years, this is a real concern, not a pedantic one. Puncture injuries from improperly stored sharps are a documented occupational and household hazard (Jagger et al., 2010, Infection Control and Hospital Epidemiology).
Second, the "$550 for four pens" figure. This is plausible for out-of-pocket brand-name GLP-1 pricing without insurance, but the number varies significantly by drug, dose, and pharmacy. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have list prices ranging from roughly $900 to $1,350 per month for brand-name versions as of 2024. Four pens at $550 would imply $137.50 per pen, which tracks more closely with compounded semaglutide pricing than brand-name pricing. The video does not clarify which product she used, so the number is unverifiable without more context.
What should you actually know?
If you are on a GLP-1 and generating used pens, here is what the evidence and regulation actually support.
- Use an FDA-cleared sharps container. They cost $5 to $15 at most pharmacies and meet puncture-resistance standards that a cheese ball jar does not.
- The safest disposal routes in the U.S. are: FDA-approved mail-back programs, authorized community collection sites (searchable at SafeNeedleDisposal.org), and household hazardous waste events. Some states also permit "destroy in place" devices.
- Do not flush injection pens. The FDA advises flushing only for certain Schedule II opioids on a specific approved list. GLP-1 pens are not on it.
- Cost transparency around GLP-1 drugs is genuinely useful public conversation. List prices are high and wildly inconsistent depending on insurance, manufacturer coupons, compounding pharmacies, and telehealth platforms. Anyone quoting a single number as "the price" is giving you incomplete information.
- If you are managing GLP-1 costs or disposal questions, your prescribing clinician or pharmacist is the right first call, not a TikTok giveaway comment section.
Bottom line
This video is mostly harmless and does more good than harm by raising sharps disposal awareness in the GLP-1 community, a group generating a lot of sharps right now. The disposal message is directionally correct. The container choice is not ideal and worth flagging. The cost figures are plausible but unverifiable. Nobody should be treating a cheese ball jar as a validated medical sharps container, regardless of how many TikTok likes the video gets.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Annie DeGracia Anderson · TikTok creator
1.7K views on this video
Shall we play a game? The first person to comment and guess the exact number of glp-1 pens in the container and the correct dollar amount I spent on myself as represented here will get a Wellness Care Package from me! So do all the things..like, follow, share and safely dispose of your sharps!! #giveaway #sharpscontainer #howto #safetyfirst #glp1community
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about fda-cleared sharps containers cost $5 to $15?
FDA-cleared sharps containers cost $5 to $15 and meet puncture-resistance standards that repurposed food containers do not. Use one.
What does the video say about fewer than 40% of u.s. counties have a publicly accessible?
Fewer than 40% of U.S. counties have a publicly accessible sharps drop-off site within 10 miles of residential areas (Yanklowitz et al., 2021, Waste Management), making this a real infrastructure gap.
What does the video say about cvs?
CVS and other retail pharmacies do not uniformly accept used sharps. Check SafeNeedleDisposal.org for authorized sites in your zip code before making the trip.
What does the video say about brand-name glp-1 medications (ozempic, wegovy, mounjaro, zepbound) carry list prices?
Brand-name GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound) carry list prices of roughly $900 to $1,350 per month as of 2024. Out-of-pocket costs vary significantly with insurance and manufacturer savings programs.
What does the video say about weekly glp-1 injections over 3 years produce approximately 156 used?
Weekly GLP-1 injections over 3 years produce approximately 156 used devices. The sharps disposal burden from GLP-1 adoption is a population-level waste management issue that pharmacy systems have not caught up with.
What does the video say about needlestick injuries from improperly discarded sharps cause an estimated 600,000?
Needlestick injuries from improperly discarded sharps cause an estimated 600,000 to 1 million injuries annually in the U.S. outside clinical settings (EPINet, 2020). This is not a theoretical risk.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Annie DeGracia Anderson, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.